BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Phase 3
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2013-07-01
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 478
- Registration Number
- NCT01890434
Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Phase 3
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2013-07-01
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 426
- Registration Number
- NCT01890421
Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)
Phase 2
Completed
- Conditions
- Constipation
- Interventions
- Drug: PlaceboDrug: Polyethylene Glycol (PEG 3350)Drug: Bisacodyl laxative tablets (rescue medication)
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 65
- Registration Number
- NCT01885104
First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: BAY1179470
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 35
- Registration Number
- NCT01881217
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Phase 2
Completed
- Conditions
- Diabetic Nephropathies
- Interventions
- Drug: Finerenone (BAY94-8862)Drug: Placebo
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 823
- Registration Number
- NCT01874431
The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
Not Applicable
Completed
- Conditions
- Contraception
- Interventions
- Device: ESS505 (BAY1454033)
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 73
- Registration Number
- NCT01861886
Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 106
- Registration Number
- NCT01855139
Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 131
- Registration Number
- NCT01855100
Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
Phase 3
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT01853319
Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet
Phase 1
Completed
- Conditions
- Biological Availability
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT01853800
Β© Copyright 2025. All Rights Reserved by MedPath